We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $21.7B
1-Year Est. Return 79.24%
This Fund
S&P 500
This Quarter Est. Return
+33.18%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$21.7B
AUM Growth
+$2.61B
Cap. Flow
-$3.46B
Cap. Flow %
-15.95%
Top 10 Hldgs %
62.14%
Holding
194
New
19
Increased
30
Reduced
23
Closed
105

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$166M
2
ROIV icon
Roivant Sciences
ROIV
+$137M
3
IMVT icon
Immunovant
IMVT
+$130M
4
BBIO icon
BridgeBio Pharma
BBIO
+$96.5M
5
BIDU icon
Baidu
BIDU
+$94.1M

Top Sells

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$498M
2
AMZN icon
Amazon
AMZN
+$398M
3
SCHW
Charles Schwab
SCHW
+$372M
4
AON icon
Aon
AON
+$365M
5
GOOG icon
Alphabet (Google) Class C
GOOG
+$286M

Sector Composition

Rank Sector Weight
1 Healthcare 54.84%
2 Miscellaneous 21.83%
3 Communication Services 8.41%
4 Technology 5.7%
5 Financials 3.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$818B
$4.48B 20.67%
6,000,000
+3,700,000
+161% +$2.68B
RVMD icon
2
Revolution Medicines
RVMD
$45.2B
$2.54B 11.71%
13,550,796
-54,000
-0.4% -$7.89M
EA
3
DELISTED
Electronic Arts
EA
$1.62B 7.49%
7,919,500
+449,500
+6% +$91M
BBIO icon
4
BridgeBio Pharma
BBIO
$14.7B
$800M 3.69%
10,743,063
+1,377,600
+15% +$96.5M
PTGX icon
5
Protagonist Therapeutics
PTGX
$9.63B
$778M 3.59%
6,348,906
– –
EXEL icon
6
Exelixis
EXEL
$14.7B
$733M 3.38%
13,468,010
+357,000
+3% +$17.4M
LQDA icon
7
Liquidia Corp
LQDA
$6.14B
$667M 3.08%
8,365,038
-291,000
-3% -$15.6M
AMZN icon
8
Amazon
AMZN
$2.79T
$628M 2.9%
2,632,994
-1,585,400
-38% -$398M
LNTH icon
9
Lantheus
LNTH
$6.59B
$619M 2.86%
5,583,479
– –
NTRA icon
10
Natera
NTRA
$47.2B
$602M 2.78%
2,218,366
-989,000
-31% -$211M
UNH icon
11
UnitedHealth
UNH
$360B
$528M 2.44%
1,270,532
-551,174
-30% -$204M
TMO icon
12
Thermo Fisher Scientific
TMO
$229B
$526M 2.43%
1,049,185
+167,700
+19% +$80.5M
ROIV icon
13
Roivant Sciences
ROIV
$24.9B
$506M 2.34%
14,309,000
+4,634,000
+48% +$137M
AON icon
14
Aon
AON
$69.4B
$459M 2.12%
1,382,562
-1,130,076
-45% -$365M
BSX icon
15
Boston Scientific
BSX
$68B
$449M 2.07%
10,521,184
+3,050,500
+41% +$166M
AVGO icon
16
Broadcom
AVGO
$1.7T
$435M 2.01%
1,151,800
-627,700
-35% -$252M
MSFT icon
17
Microsoft
MSFT
$3.79T
$415M 1.92%
1,112,863
-1,231,916
-53% -$498M
TNGX icon
18
Tango Therapeutics
TNGX
$3.84B
$384M 1.77%
12,277,000
+3,179,589
+35% +$78.6M
KKR icon
19
KKR & Co
KKR
$98.5B
$378M 1.74%
4,118,300
-553,500
-12% -$53.7M
SNPS icon
20
Synopsys
SNPS
$79.8B
$370M 1.71%
829,600
-383,700
-32% -$180M
BEAM icon
21
Beam Therapeutics
BEAM
$3.04B
$351M 1.62%
10,236,396
+101,700
+1% +$3.07M
CRNX
22
DELISTED
Crinetics Pharmaceuticals
CRNX
$336M 1.55%
8,989,098
+651,000
+8% +$24.2M
GRAL
23
GRAIL Inc
GRAL
$3.6B
$284M 1.31%
4,161,584
+907,900
+28% +$53.5M
WAB icon
24
Wabtec
WAB
$47.4B
$241M 1.11%
894,503
-714,900
-44% -$189M
IMVT icon
25
Immunovant
IMVT
$8.08B
$224M 1.03%
5,805,000
+4,259,000
+275% +$130M
1
2 3 4 5

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Farallon Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Farallon Capital Management held 194 positions worth $21.7B, up 14% from $19.1B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Farallon Capital Management withdrew a net $3.46B in Q2 2026, closing 105 positions and reducing 23 holdings. Its most notable exit was Charles Schwab, an estimated $372M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, up from 47% a quarter earlier, followed by Miscellaneous and Communication Services.

Against the trend, Farallon Capital Management opened a new position in Parabilis Medicines Inc worth $64.8M.

  • Farallon Capital Management's largest Q2 2026 buy was Parabilis Medicines Inc: 2,368,200 shares worth $64.8M.
  • Farallon Capital Management added most to Boston Scientific in Q2 2026, an estimated $166M increase.
  • Farallon Capital Management's biggest Q2 2026 reduction was Microsoft, cutting an estimated $498M.
  • Farallon Capital Management fully exited Charles Schwab in Q2 2026, selling an estimated $372M.
  • Farallon Capital Management's ten largest holdings make up 62% of its $21.7B portfolio in Q2 2026.
  • Farallon Capital Management opened 19 new positions and closed 105 in Q2 2026.
  • Farallon Capital Management's portfolio value rose 14% quarter-over-quarter to $21.7B.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.